Fluorine 18 MK 6240

Drug Profile

Fluorine 18 MK 6240

Alternative Names: [18F]MK 6240; Fluorine-18-MK6240

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Imaging agents; Radiopharmaceuticals
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 06 Jan 2017 Cerveau Technologies enters into an exclusive license agreement with Merck for the global development and commercialisation of MK 6240
  • 06 Jan 2017 Cerveau intends to initiate a phase III clinical program in early 2018
  • 25 Jul 2016 Merck Sharp and Dohme enters into a research collaboration with Enigma Biomedical Group to study qualification and validation of fluorine 18 MK 6240
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top